| Vol. 13.26 – 15 July, 2021 |
| |
|
|
| Researchers reported that cells derived from claudin-low mammary tumors, a mesenchymal subtype of TNBC, exhibited a distinctive organoid structure with extended “spikes” in 3D matrices. [Nature Communications] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators identified v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (MAFF) as a potent regulator of tumor invasion without affecting cell viability, and demonstrated the oncogenic role of MAFF as an activator of the IL11/STAT3 pathways in breast cancer. [Nature Communications] |
|
|
|
| Scientists used a network-based mathematical model to identify sensitivity regulators and drug combinations for the PI3Kα inhibitor alpelisib in ER+ PIK3CA mutant breast cancer. The combination of alpelisib and BH3 mimetics, e.g., MCL1 inhibitors, was experimentally validated in ER+ breast cancer cell lines. [Cancer Research] |
|
|
|
| Researchers leveraged human epidermal-growth-factor receptor-2 (HER2) overexpression to engage antibody-dependent cellular phagocytosis through a combination of trastuzumab and anti-CD47 macrophage checkpoint immunotherapy. [Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Mesenchymal stem cells and cancer-associated fibroblasts expressed high PEAK1 protein levels and potentiated tumorigenesis, lapatinib resistance and metastasis of HER2-positive breast cancer cells in a Pseudopodium-Enriched Atypical Kinase One (PEAK1)-dependent manner. [Oncogene] |
|
|
|
| Loss-of-function study was used to evaluate the effects of Proteasome 26S subunit ATPase 2 (PSMC2) knockdown in cell proliferation, apoptosis and migration. Knockdown of PSMC2 suppressed breast cancer progression in vitro and in vivo. [Cell Death & Disease] |
|
|
|
| The authors identified the consistent transcriptome of primary breast cancer stem cells (BCSCs) shared across breast cancer subtypes, and examined the clinical relevance of ITGA7, one of the genes differentially expressed in BCSCs. [British Journal of Cancer] |
|
|
|
| Depletion or inhibition of WNK1 reduced migration of several breast cancer cell lines in wound healing assays and decreased invasion in collagen matrices. [Molecular Cancer therapeutics] |
|
|
|
| WZ-2-033 significantly inhibited the proliferation, colony survival, migration, and invasion of TNBC cells and gastric cancer cells with aberrant signal transducer and activator of transcription 3 (STAT3) activation. [Acta Pharmacologica Sinica] |
|
|
|
| Investigators explored bone metastasis-related long non-coding RNAs (lncRNAs) in breast cancer and found that four LncRNA-mRNA pairs, including LOC641518-LEF1, may have played a central role in breast cancer bone metastasis. [Cancer Cell International] |
|
|
|
| Researchers developed bispecific antibodies for T-cell retargeting to HER3-expressing tumor cells, utilizing either a single-chain diabody format (scDb) with one binding site for HER3 and one for CD3 on T-cells or a trivalent bispecific scDb-scFv fusion protein exhibiting an additional binding site for HER3. [Scientific Reports] |
|
|
|
| SET, an endogenous inhibitor of protein phosphatase 2A, was overexpressed in all subtypes of invasive breast carcinoma tissues. Treatment with SET-targeted siRNAs reduced the motility of MCF-7 and MDA-MB-231 cells in transwell assay. [Scientific Reports] |
|
|
|
|
| The authors review how cell fate decisions are regulated by components of the microenvironment during mammary gland development and how pathological changes in the microenvironment can alter cell fates, leading to malignancy. [Developmental Cell] |
|
|
|
| Scientists provide a comprehensive overview of the available evidence directly linking hormones to breast cancer stem cell biology. [Molecular and Cellular Endocrinology] |
|
|
|
|
| CytoDyn, Inc., a biotechnology company developing leronlimab, a CCR5 antagonist, announced its clinical trial with leronlimab in combination with carboplatin for the treatment of metastatic TNBC has advanced from Phase Ib to a Phase II trial. [CytoDyn, Inc.] |
|
|
|
| Translational Research in Oncology (TRIO) announced enrollment completion in coopERA Breast Cancer, a Phase II clinical trial of giredestrant, an oral selective estrogen receptor degrader that showed encouraging tumor activity both alone and in combination with palbociclib in estrogen-receptor-positive metastatic breast cancer patients. [Translational Research in Oncology] |
|
|
|
|
| October 7 – 11, 2021 Virtual |
|
|
|
|
|
| University of Pittsburgh – Pittsburgh, Pennsylvania, United States |
|
|
|
| Medical University of South Carolina – Charleston, South Carolina, United States |
|
|
|
| Karolinska Institutet – Stockholm, Sweden |
|
|
|
| Mayo Clinic Health System – Rochester, Minnesota, United States |
|
|
|
| University of Michigan – Ann Arbor, Michigan, United States |
|
|
|
|